Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Intellia Therapeutics (NASDAQ:NTLA) announced on December 1, 2025 that it granted inducement equity awards to three new employees under its 2024 Inducement Plan as material inducements to employment.

The awards are time-based restricted stock units totaling 12,600 shares, vesting in thirds on December 1, 2026, 2027, and 2028, and are subject to continued service through each vesting date. The grants were approved by the compensation committee and were made outside the company’s shareholder-approved equity incentive plans pursuant to Nasdaq Listing Rule 5635(c)(4).

Key Figures

Inducement RSUs granted 12,600 shares Aggregate time-based RSUs granted to three new employees on Dec 1, 2025

New employees 3 employees Recipients of inducement equity awards under 2024 Inducement Plan

First vesting date Dec 1, 2026 One-third of RSUs vest on this date, subject to continued service

Second vesting date Dec 1, 2027 Second one-third of RSUs vest on this date

Final vesting date Dec 1, 2028 Final one-third of RSUs vest on this date

Inducement plan year 2024 Year of Intellia’s Inducement Plan used for these grants

Market Reality Check

$9.77 Last Close

Volume Volume 5,119,117 is below 20-day average 7,009,848 (relative volume 0.73x). normal

Technical Shares at $9.765 are trading below the 200-day MA of $11.4, well under the $28.25 52-week high.

Peers on Argus

NTLA gained 7.78% while several biotech peers (DNTH, ELVN, ZYME) showed smaller gains around 1–3%, RCUS was slightly negative and TRML was flat, and no sector-wide momentum was flagged by scanners.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 10	Clinical data update	Positive	+2.2%	Longer-term Phase 1 ATTR-CM data for nex-z with sustained TTR reduction.
Nov 08	Clinical data update	Positive	+2.2%	Pooled Phase 1/2 HAE data for lonvo-z showing high attack-free rates.
Nov 06	Earnings and pipeline	Negative	-9.2%	Q3 2025 results plus disclosure of FDA clinical hold on Phase 3 nex-z trials.
Oct 27	Safety trial pause	Negative	-42.2%	Temporary pause of MAGNITUDE trials after Grade 4 liver event and bilirubin rise.
Oct 03	Inducement grants	Neutral	+2.9%	Inducement RSU grants to six new employees under 2024 Inducement Plan.

Pattern Detected

News-driven moves have generally aligned with the tone of clinical and regulatory updates, with sharp declines on safety/hold events and modest gains on positive data and routine items.

Recent Company History

Over the last few months, Intellia has cycled through major clinical and regulatory events. In late October 2025, the MAGNITUDE and MAGNITUDE‑2 trials of nex‑z were paused after a Grade 4 liver event, followed by an FDA clinical hold, driving large negative moves. Earlier and later, positive Phase 1 and pooled Phase 1/2 data for nex‑z and lonvo‑z supported modest gains. A prior October 1, 2025 inducement grant under the 2024 Inducement Plan also coincided with a small positive reaction, similar in nature to today’s announcement.

Market Pulse Summary

This announcement details a modest equity-based hiring tool: 12,600 time‑based RSUs granted to three new employees under the 2024 Inducement Plan, vesting annually from 2026 to 2028 under Nasdaq Listing Rule 5635(c)(4). Relative to prior catalysts—such as MAGNITUDE safety events and Phase 1/2 data for nex‑z and lonvo‑z—this is a routine governance item. Investors may monitor future clinical updates and any changes in capital structure for more material drivers.

Key Terms

restricted stock units financial

"The inducement grants consisted of time-based restricted stock units (“RSUs”)"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

RSUs financial

"time-based restricted stock units (“RSUs”) for an aggregate of 12,600 shares"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

Nasdaq Listing Rule 5635(c)(4) regulatory

"as a material inducement to entering into employment ... in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

equity incentive plans financial

"awards were granted outside of Intellia’s stockholder-approved equity incentive plans"

Equity incentive plans are company programs that pay employees, executives, or directors with company stock, stock options, or share units instead of or in addition to cash, aiming to align their interests with shareholders—like giving team members a stake in the house they help build. For investors this matters because such plans can motivate better company performance but also dilute existing ownership and increase reported compensation costs, so they affect future earnings, voting power, and share value.

inducement grants financial

"it awarded inducement grants to three new employees under Intellia’s 2024 Inducement Plan"

Inducement grants are special awards of shares or stock options given to new employees to encourage them to join a company or accept a new role. They act like a welcome bonus, providing an extra incentive to attract talent. For investors, these grants can impact a company's costs and share structure, influencing the value of their investments.

AI-generated analysis. Not financial advice.

CAMBRIDGE, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on December 1, 2025, it awarded inducement grants to three new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment.

The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate of 12,600 shares of Intellia’s common stock, with one-third of such RSUs vesting on December 1, 2026, 2027 and 2028.

All equity vesting is subject to each employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.

All of the above-described awards were granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, which was adopted by the board of directors in June 2024. These awards were approved by Intellia’s compensation committee as a material inducement to entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).

About Intellia Therapeutics

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx.

Intellia Contacts:

Investors:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
jason.fredette@intelliatx.com

Media:
Matt Crenson
Ten Bridge Communications
media@intelliatx.com
mcrenson@tenbridgecommunications.com

FAQ

What did Intellia (NTLA) announce on December 1, 2025 regarding inducement grants?

Intellia granted time-based RSUs totaling 12,600 shares to three new employees as inducements to employment.

When do the Intellia (NTLA) inducement RSUs vest?

The RSUs vest in equal thirds on December 1, 2026, 2027, and 2028, subject to continued service.

Why were the Intellia (NTLA) awards granted outside existing equity plans?

The awards were issued under Intellia’s 2024 Inducement Plan and approved as material inducements in accordance with Nasdaq Listing Rule 5635(c)(4).

How many employees received inducement awards from Intellia (NTLA)?

Three new employees received the inducement restricted stock unit awards.

Do Intellia (NTLA) inducement RSUs carry additional service conditions?

Yes; all equity vesting is conditioned on each recipient’s continued service as an employee or service provider through each vesting date.